These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32083758)

  • 21. Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.
    Lu XL; Liang ZH; Zhang CE; Lu SJ; Weng XF; Wu XW
    Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):157-63. PubMed ID: 16518539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma.
    Eladl AE; Shimada K; Suzuki Y; Takahara T; Kato S; Kohno K; Elsayed AA; Wu CC; Tokunaga T; Kinoshita T; Sakata-Yanagimoto M; Nakamura S; Satou A
    Cancer Med; 2020 Jan; 9(2):678-688. PubMed ID: 31793218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.
    Gallot G; Vollant S; Saïagh S; Clémenceau B; Vivien R; Cerato E; Bignon JD; Ferrand C; Jaccard A; Vigouroux S; Choquet S; Dalle JH; Frachon I; Bruno B; Mothy M; Mechinaud F; Leblond V; Milpied N; Vié H
    J Immunother; 2014 Apr; 37(3):170-9. PubMed ID: 24598452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
    Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
    Secondino S; Pedrazzoli P; Basso S; Bossi P; Bianco A; Imarisio I; Pagani A; De Cicco M; Muscianisi S; Casanova M; Morosi C; Bergamini C; Benazzo M; Cossu Rocca M; Perotti C; Baldanti F; Zecca M; Licitra LF; Comoli P
    Front Immunol; 2023; 14():1208475. PubMed ID: 37497213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
    Gerdemann U; Katari U; Christin AS; Cruz CR; Tripic T; Rousseau A; Gottschalk SM; Savoldo B; Vera JF; Heslop HE; Brenner MK; Bollard CM; Rooney CM; Leen AM
    Mol Ther; 2011 Dec; 19(12):2258-68. PubMed ID: 21915103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases.
    Rodriguez J; Romaguera JE; Manning J; Ordonez N; Ha C; Ravandi F; Cabanillas F
    Leuk Lymphoma; 2000 Sep; 39(1-2):139-44. PubMed ID: 10975392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
    Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
    Straathof KC; Bollard CM; Popat U; Huls MH; Lopez T; Morriss MC; Gresik MV; Gee AP; Russell HV; Brenner MK; Rooney CM; Heslop HE
    Blood; 2005 Mar; 105(5):1898-904. PubMed ID: 15542583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
    Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
    Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma.
    Hashimoto A; Asai S; Tanaka Y; Shinzato I
    Eur J Case Rep Intern Med; 2021; 8(10):002533. PubMed ID: 34790617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.